Physician profile
Said Uddin
NPI 1205938867
$3,655.10
in general payments reported to CMS, 2019-2025
24 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $466 · 2021: $704 · 2022: $668 · 2023: $373 · 2024: $298 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $946.47 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $619.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $412.83 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $206.63 | 2019-2022 | |
| Lilly USA, LLC | $182.18 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $169.73 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $146.98 | 2019-2023 | |
| Dexcom, INC. | $132.89 | 2021-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $102.52 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $94.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.57 | 2019-2023 | |
| Amarin Pharma, INC. | $75.53 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $67.42 | 2023-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.29 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $43.70 | 2021 | |
| Mylan Specialty L.P. | $37.62 | 2019-2020 | |
| Allergan, INC. | $36.23 | 2019 | |
| Exact Sciences Corporation | $32.78 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $27.76 | 2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.45 | 2021-2024 | Xifaxan |
| Athena Bioscience, LLC | $16.67 | 2023 | Qdolo |
| Eisai INC. | $13.50 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Said Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.